1. Home
  2. ACOG vs CODA Comparison

ACOG vs CODA Comparison

Compare ACOG & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACOG
  • CODA
  • Stock Information
  • Founded
  • ACOG 2000
  • CODA 1994
  • Country
  • ACOG Canada
  • CODA United States
  • Employees
  • ACOG N/A
  • CODA N/A
  • Industry
  • ACOG
  • CODA Industrial Machinery/Components
  • Sector
  • ACOG
  • CODA Industrials
  • Exchange
  • ACOG Nasdaq
  • CODA Nasdaq
  • Market Cap
  • ACOG 80.3M
  • CODA 88.7M
  • IPO Year
  • ACOG N/A
  • CODA N/A
  • Fundamental
  • Price
  • ACOG $10.69
  • CODA $8.23
  • Analyst Decision
  • ACOG Strong Buy
  • CODA Strong Buy
  • Analyst Count
  • ACOG 1
  • CODA 1
  • Target Price
  • ACOG $20.00
  • CODA $11.00
  • AVG Volume (30 Days)
  • ACOG 67.3K
  • CODA 62.4K
  • Earning Date
  • ACOG 08-14-2025
  • CODA 06-16-2025
  • Dividend Yield
  • ACOG N/A
  • CODA N/A
  • EPS Growth
  • ACOG N/A
  • CODA 21.86
  • EPS
  • ACOG N/A
  • CODA 0.30
  • Revenue
  • ACOG $2,928,654.00
  • CODA $22,758,966.00
  • Revenue This Year
  • ACOG N/A
  • CODA $11.64
  • Revenue Next Year
  • ACOG N/A
  • CODA $14.53
  • P/E Ratio
  • ACOG N/A
  • CODA $27.13
  • Revenue Growth
  • ACOG N/A
  • CODA 24.78
  • 52 Week Low
  • ACOG $3.75
  • CODA $5.76
  • 52 Week High
  • ACOG $11.40
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • ACOG N/A
  • CODA 64.79
  • Support Level
  • ACOG N/A
  • CODA $7.78
  • Resistance Level
  • ACOG N/A
  • CODA $8.46
  • Average True Range (ATR)
  • ACOG 0.00
  • CODA 0.59
  • MACD
  • ACOG 0.00
  • CODA 0.06
  • Stochastic Oscillator
  • ACOG 0.00
  • CODA 70.79

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

Share on Social Networks: